WO1993022290A1 - Novel substituted tertiary amino compound or salt thereof - Google Patents
Novel substituted tertiary amino compound or salt thereof Download PDFInfo
- Publication number
- WO1993022290A1 WO1993022290A1 PCT/JP1993/000548 JP9300548W WO9322290A1 WO 1993022290 A1 WO1993022290 A1 WO 1993022290A1 JP 9300548 W JP9300548 W JP 9300548W WO 9322290 A1 WO9322290 A1 WO 9322290A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- ring
- amino
- pyrimidine
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- Newly substituted tertiary amino compounds or salts thereof are described.
- the present invention relates to a novel substituted tertiary amino compound having an aromatase inhibitory activity useful as a medicament, a pharmaceutically acceptable salt thereof, a production method thereof, or a pharmaceutical composition containing the same.
- Aromatase is a substance that uses an androgen as a substrate to aromatize the steroid A ring to produce estrogen. By inhibiting this enzymatic activity, aromatase can be used to prevent and treat various diseases in which estrogen is an adverse factor. It becomes possible.
- U.S. Pat.No. 4,774,251 discloses a compound represented by the following general formula having a pyridyl or virazyl-substituted tertiary amino group and further having one or two phenyl groups. It is described that it exhibits aromatase inhibitory activity.
- the compound of the present invention is different from the compound described in the above prior art document in that the compound of the present invention always has a pyrimidine ring, a pyridazine ring or a triazine ring as a basic structure. Are clearly different in structure.
- the compound of the present invention has an activity of inhibiting aloma kinase, which is 100 times or more stronger than the compounds described in the above-mentioned prior art documents, and its excellent usefulness has been confirmed.
- n an integer from 1 to 6
- X an oxygen atom, a sulfur atom or a group represented by the formula CH 2
- Ring B pyrimidine ring, pyridazine ring or triazine ring.
- Ring D, ring E same or different, optionally substituted aryl group, optionally substituted 5- or 6-membered having 1 to 3 heteroatoms consisting of nitrogen, oxygen or sulfur atoms A heterocyclic group or an optionally substituted bicyclic fused heterocyclic group in which the heterocycle is fused to a benzene ring
- the “lower alkyl group” which is one of the substituents that the ring D and the ring E may have, specifically, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, Isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, tert-pentyl group, 1-methylbutyl group, 2-methylbutyl group, 1,2-dimethylpropyl group, hexyl group, Sohexyl group, 1-methylpentyl group, 2-methylpentyl group, 3-methylpentyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-dimethylbutyl group, 1,3-dimethyl Butyl group, 2,3-dimethylbutyl group, 3,3-dimethylbutyl group, 1,
- the “lower alkylene group” is a straight-chain or branched carbon chain having 1 to 6 carbon atoms, specifically, for example, methylene go, ethylene group, propylene group, tetramethylene group, 2 —Methyltrimethylene group, 1-ethylethylene group, pentamethylene group, 1,2-ethylethylene group and the like, preferably methylene group and ethylene group.
- the "aryl group” constituting the “aryl group which may be substituted” which means the rings D and E includes a phenyl group, a naphthyl group, an anthracenyl group, a phenanthrenyl group and the like;
- a heteroatom 1 comprising a nitrogen atom, an oxygen atom or a sulfur atom which constitutes an optionally substituted 5- or 6-membered heterocyclic group having 1 to 3 heteroatoms consisting of an oxygen atom or a sulfur atom
- Examples of the 5- or 6-membered 5- or 6-membered heterocyclic group having 3 to 3 groups include a furyl group, a benzyl group, a thiazolyl group, a thiaziazolyl group, an oxazolyl group, an imidazolyl group, a triazolyl group, a pyrrolinole group, a pyridyl group, A pyrimidinyl group and a birazinyl group.
- the ⁇ 2-condensed heterocyclic group in which the heterocyclic group is condensed with a benzene ring which may be substituted ''
- the ⁇ 2-condensed heterocyclic group in which the heterocyclic group is condensed with a benzene ring '' is
- a heterocyclic group consisting of benzothiazole, benzoxazole, quinoline, isoquinoline, benzotriazole, and benzofurazan.
- an "aryl ring group” a “5- or 6-membered heterocyclic group having 1 to 3 heteroatoms consisting of a nitrogen atom, an oxygen atom or a sulfur atom” and "2
- the “ring-fused heterocyclic group” may have one or more, preferably one or two substituents.
- Examples of such a substituent include a halogen atom, a cyano group, Cyano lower alkyl group, nitro group, trifluoromethyl group, hydroxy group, amino group, mono- or di-lower alkylamino group, lower alkyl group, lower alkoxy group, carboxy group, lower alkoxy carbonyl group, Lower alkanoyl, lower alkanoyloxy, lower alkanoylamino, aroyl, aroyloxy, carbamoyl, mono or di-lower alkylaminocarbonyl, sulfonic acid, lower alkylsulfonyl, sulfamoyl And mono- or di-lower alkylsulfamoyl groups, preferably halogen atom, cyano group, cyano lower alkyl group, nitro group, trifluoromethyl group, hydroxy group, amino group, lower group.
- halogen atom is a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom
- lower alkoxy group is a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group.
- the “lower alkoxycarbonyl group” includes a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, a butoxycarbonyl group, a tert-butoxycarbonyl group, a pentyloxy group.
- Examples of the “lower alkanoyl (oxy) group” include an acetyl (oxy) group, a propionyl (aminoxyl) group, a petyryl (oxy) group, a valeryl (oxy) group, and an isovaleryl (oxyxy) group.
- lower alkyl group examples include the lower alkyl groups described above. Representative groups include methylaminocarbonyl, dimethylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, methylsulfamoyl, dimethylinolesulfamoyl, and dimethylaminosulfamoyl. And the like.
- the “lower alkylsulfonyl group” includes methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl Group, pentylsulfonyl group, hexylsulfonyl group and the like.
- the compound of the present invention can easily form a salt with an inorganic acid or an organic acid, and these salts have an aromatase inhibitory activity like the free base.
- Suitable salts include, for example, hydrochloride, hydrobromide, Inorganic acid salts such as sulfate, nitrate and phosphate, and organic acid salts such as oxalate, fumarate and tartrate can be mentioned. .
- a salt with a pharmaceutically acceptable alkali metal or alkaline earth metal for example, sodium, potassium, magnesium or calcium
- a salt with an organic amine such as ammonia or triethylamine, or the like.
- the compound of the present invention may have an asymmetric carbon atom depending on the type of the substituent and the like, and the compound of the present invention includes all isomers based on these, such as optical isomers (distereomers, optically active isomers).
- the compounds of the present invention include all compounds, such as isolated compounds and mixtures thereof.
- the compound of the present invention can be produced by applying various synthetic methods, utilizing the characteristics based on the basic skeleton or the type of the substituent. Hereinafter, typical production methods are shown.
- the method for producing the target compound (() from the raw material compound (H) is as follows. As mentioned above, this can be done by two routes. Employing these routes The reaction of each step used is alkylation or acylation of an amino group, and both reactions can be carried out similarly. .
- a reaction-corresponding amount of the starting compound is prepared in the presence of a base in a solvent inert to this reaction such as dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dimethyloxetane, acetone, and methylethylketone.
- a base for example, sodium hydride, sodium amide, n-butyllithium, potassium t-butoxide, sodium, sodium methoxide, sodium methoxide, sodium hydroxide, sodium hydroxide, and hydration power can be used. This reaction can be easily performed at room temperature.
- the arylsulfonyloxy group includes, for example, a phenylsulfonyloxy group and a paratoluenesulfonyloxy group
- the lower alkylsulfonyloxy group includes a methylsulfonyloxy group and an ethylsulfonyloxy group.
- alkoxy group, c which may be mentioned propylsulfonyl O carboxymethyl been sulfonyl Ruokishi group substituted with a lower alkyl group such as a group
- a 1 represents a lower alkylene group having one less methylene group than A. The same applies hereinafter.
- a corresponding Schiff base (K) is produced by the reaction of an amino compound ( ⁇ ) and an aldehyde compound (W), which is then reduced to a compound (XI). Similarly, alkylation or acylation is performed to obtain the desired compound (la).
- the formation reaction of the Schiff base can be carried out in an alcohol such as methanol or ethanol or a solvent such as benzene or toluene by an azeotropic dehydration reaction under an acid catalyst.
- the reduction is performed by a conventional method using, for example, sodium borohydride, lithium borohydride, sodium cyanoborohydride, or the like.
- reaction solvent examples include alcohols such as methanol and ethanol, organic solvents such as sulfuric acid, water, and a mixed solvent thereof.
- a Schiff base can be isolated without adding a reducing agent to the reaction solution containing the Schiff base.
- R 1 is a protecting group for an amino group
- Y is a halogen atom
- B 1 and D 1 are each an aryl group substituted with a nitro group, a 5- or 6-membered heterocyclic group, or the heterocyclic group.
- B 2 is Ariru ring group substituted with Amino group, heterocyclic group 5 or 6-membered, or the heterocyclic group is condensed with a benzene ring
- B 3 is an aryl ring group substituted with a halogen atom, a 5- or 6-membered hetero ring group, or a two-ring fused ring in which the heterocyclic group is fused with a benzene ring. Means the same.
- This production method is a method for obtaining the compound of the present invention substituted with a halogen atom represented by the general formula (Ib) or (Ic).
- the compound represented by the general formula (xm) or (XVI) is reduced to obtain an amino compound represented by the general formula (xw) or (xw), and then subjected to a Sandmeyer reaction to introduce a hagen atom. Thereafter, the protecting group is removed to obtain a compound represented by the general formula (XV) or (XI), and the compound can be obtained by reacting the compound with the compound (V) or (m).
- Reduction of the compound represented by the general formula (xm) is performed by a conventional method such as chemical reduction or catalytic reduction.
- Suitable reducing agents for use in the chemical reduction include metals such as tin, zinc and iron, and examples of the catalytic reduction include platinum catalysts such as platinum and platinum oxide, palladium catalysts such as palladium black and palladium oxide, and Raney nickel. And a conventional catalyst method using a nickel catalyst such as As a solvent in this case, a conventional solvent such as methanol, ethanol, propanol, and ethyl acetate is used.
- the protection of the nitrogen atom of the compound represented by the general formula (Xm) or (X7I) is a commonly used acyl-protecting group such as an acetyl group or a benzoyl group.
- the introduction of this protecting group 4 The reaction can be carried out by reacting an acid anhydride, acetyl chloride, benzoyl chloride or the like in the presence of a base such as sodium diacid, pyridine, picoline, lutidine, trimethylamine or tritylamine.
- a base such as sodium diacid, pyridine, picoline, lutidine, trimethylamine or tritylamine.
- the solvent may be dichloromethane, dichloroethane, chloroform, benzene, toluene, or the like, or may be solventless.
- the compound or (XW) thus obtained can be converted to a compound (XV) or (X 0) by carrying out a Sandmeyer reaction, introducing a halogen atom and then removing the protecting group.
- the Sandmeyer reaction can be carried out by a conventional method using cuprous chloride, cuprous bromide, cuprous iodide and hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, or the like.
- the solvent is water, acetone, dioxane, tetrahydrofuran, etc.
- the protective group is removed by acid hydrolysis with dilute hydrochloric acid, dilute sulfuric acid, etc.
- the compound (XV) thus obtained and the compound ( The reaction with (V) or (m) is based on
- the compound of the present invention has a lower alkanoylamino group as a substituent, it can be obtained by a method of reacting the compound of the present invention having a corresponding amino group with dihydric anhydride or the like according to a conventional method.
- a benzotriazolyl group as a substituent of the compound of the present invention
- the amino group (or mono-substituted amino group) and the nitro group of the compound having a nitro group are reduced as adjacent substituents of the fuunyl group, and once reduced to an amino group, It can be obtained by reacting thorium, potassium nitrite and the like and subjecting it to a ring closure reaction.
- the compound of the present invention thus produced can be isolated and purified by a known method, for example, extraction, precipitation, fractional chromatography, fractional crystallization, recrystallization and the like.
- the salt of the compound of the present invention can be converted into a desired salt by subjecting the salt to a usual salt formation reaction.
- the compound of the present invention has an action of inhibiting the activity of aromatase, which is an aromatizing enzyme involved in the production of estrogen from androgen in vivo. Therefore, the compounds of the present invention are not useful as prophylactic or therapeutic agents for various diseases in which estrogen is involved as an exacerbating factor, such as breast cancer, mastopathy, endometriosis, benign prostatic hyperplasia, uterine fibroids, and endometrial cancer.
- the medicinal effect of the compound of the present invention was measured by the following method.
- estradiol production in rats In vivo P and harmful activity
- a pregnancy horse serum gonadotropin (PMSG) 100 IU / rat was subcutaneously injected into a 60 g immature female Wister rat. 72 hours later, a test compound suspension suspended in 20% polyethylene glycol 0.5 ⁇ 1 was administered orally. The control group received only 20% polyethylene glycol.
- the rats were sacrificed by decapitation, the ovaries were collected, and the concentration of estradiol in the ovaries was measured by RI.
- Antitumor activity against breast cancer was measured in female sprag-dawley (Sprague-Daw1ay) rat dimethylbenzantracene (DMBA) -induced animal tumors.
- This experimental method is generally used as a method for measuring antitumor activity using an animal model of breast cancer.
- Inhibitory activity of the compounds was determined by suppression of 3 E 2 0 liberated from [1, 2 one 3 H] androstenedione in human placenta microsomes.
- control compounds are the compounds having the strongest aromatase inhibitory activity among the compounds described in Amerili Patent No. 4, T62,836 or Amerili Patent No. 4,774,251.
- the compounds of the present invention also showed significantly stronger activity in comparison with these compounds.
- the compound of the present invention (Example 34) was orally administered to a rat, which is an experimental animal model for breast cancer, for 2 weeks at a daily dose of 0.04 to: L OmgZKg.
- the administration suppressed or regressed the enlargement of tumors such as the mammary gland.
- the compound of the present invention may be effective also in diseases such as human breast cancer. 4. Invitro inhibitory activity of aromatase on human placenta-derived microsomes,
- the compound of the present invention also showed a very strong activity in inhibiting aromatase invitro in human placenta-derived microsomes.
- Steroid hormones other than estrogen include aldosterone, cortisol, testosterone and the like, and have been shown to have various vital physiological actions. .
- the compounds of the present invention showed almost no inhibitory activity.
- the compound of the present invention can be used as a steroid hormone other than estrogen. Since it is a selective aromatase inhibitor with little effect on rumon, it is expected to be a highly safe compound with few side effects.
- the compound of the present invention is a compound having excellent durability and a favorable profile as a drug.
- the compound of general formula (I), a non-toxic salt thereof, or a hydrate thereof is usually orally or parenterally administered for the above purpose.
- the dosage varies depending on the age, body weight, illness, therapeutic effect, administration method, treatment time, etc., but is usually 0.1 mg to 100 mg, preferably about 1 mg per day per adult. It is orally administered in the range of 10 mg once to several times a day, or in the range of 0.1 mg to 100 mg per day per adult, divided from once to several times a day. Parenteral administration or continuous intravenous administration for 1 hour to 24 hours daily. Since the dose varies under various conditions, a dose smaller than the above dose range may be sufficient.
- the solid composition for oral administration examples include tablets, powders, granules and the like.
- the one or more active substances include at least one inert diluent, such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone. It is mixed with magnesium aluminate meta-gait.
- the composition may contain additives other than inert diluents, such as lubricants such as magnesium stearate, disintegrants such as calcium cellulose glycolate, and stabilizing agents such as lactose.
- solubilizing agents such as glutamic acid or aspartic acid. Tablets or pills
- the film may be coated with a film of a gastric or enteric substance such as sucrose, gelatin, hydroxypropylcellulose and hydroxypropylmethylcellulose phthalate.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like, and commonly used inert diluents such as purified water , Including ethanol.
- the composition may contain, in addition to the inert diluent, wetting agents, suspending agents such as suspending agents, sweetening agents, flavoring agents, flavoring agents, and preservatives.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- Aqueous solutions and suspensions include, for example, distilled water for injections and physiological saline.
- water-insoluble solutions and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, and polysorbate 80.
- Such compositions may further comprise adjuvants such as preservatives, wetting agents, emulsifying agents, dispersing agents, stabilizing agents (eg, lactose), dissolution aids (eg, glutamic acid, axipartic acid). .
- Example 2 In the same manner as in Example 1, the following compounds of Examples 2 to 25 were obtained.
- Example 2
- Example 10 Dissolve 110 mg of 5-CN-[(2-bromopyridine-15-methyl) methyl] --- N- (4-cyanophenyl) amino] pyrimidine obtained in Example 4 in a small amount of ethyl acetate. 4N hydrochloric acid monoacetic acid with stirring 5 ml of an ethyl solution was added, and the mixture was stirred as it was for several hours. The resulting hydrochloric acid salt was washed with an appropriate amount of ethyl acetate to obtain 9 Omg of pale yellow crystals. Elemental analysis (as C 17 H 12 N 5 B r C 1)
- the residue was purified by silica gel column chromatography, and crude crystals were obtained from the eluate of the chromate form.
- the crude crystals were recrystallized from a mixed solvent of ethyl acetate and ether to obtain 0.25 g of 5-CN- (3-promo 4-fluorobenzyl) -N- (4-cyanophenyl) amino] pyrimidine.
- Example 30 The following compounds of Examples 30 to 51 were obtained in the same manner as in Example 29.
- Example 30
- Tables 1 to 15 list the chemical structural formulas of the compounds obtained in the above Reference Examples and Examples. ⁇ table 1 ⁇
- Tables 16 to 20 list the chemical structures it ⁇ of the other compounds of the present invention (Examples II to 30).
- Example 3 Compound 1.0 mg Lactose 76.4 mg Constarch 19.3 mg Hydroxypropylcellulose 3.0 mg
- Magnesium acid (2.1 g) was added to a tablet of 10 Omg per tablet using a rotary tableting machine (Hata Iron Works) using a ⁇ 6.5 mm x 7.8 R mortar ⁇ this tablet
- a coating apparatus manufactured by Freund Corporation
- a coating containing 20.3 g of hydroxypropylmethylcellulose, 600.2.8 g of polyethylene dalicol, 11.2 g of titanium oxide and 0.7 g of talc was used.
- the coating solution was sprayed with 350 g to give a film coated tablet coated with 5 mg per tablet.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93909428A EP0640595B1 (en) | 1992-04-28 | 1993-04-27 | Substituted tertiary amino compound or salt thereof |
US08/325,383 US5538976A (en) | 1992-04-28 | 1993-04-27 | Substituted tertiary amino compound or salt thereof |
DK93909428T DK0640595T3 (da) | 1992-04-28 | 1993-04-27 | Substituerede tertiære aminoforbindelser og salte heraf |
KR1019940703846A KR0163624B1 (ko) | 1992-04-28 | 1993-04-27 | 신규의 치환된 3급 아미노 화합물 또는 이의 염 |
CA002118138A CA2118138A1 (en) | 1992-04-28 | 1993-04-27 | Novel substituted tertiary amino compound or salt thereof |
DE69324141T DE69324141T2 (de) | 1992-04-28 | 1993-04-27 | Substituierte tertiäre amine und deren salze |
GR990401545T GR3030472T3 (en) | 1992-04-28 | 1999-06-09 | Novel substituted tertiary amino compound or salt thereof. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4/137762 | 1992-04-28 | ||
JP13776292 | 1992-04-28 | ||
JP23429892 | 1992-08-10 | ||
JP4/234298 | 1992-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993022290A1 true WO1993022290A1 (en) | 1993-11-11 |
Family
ID=26470979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/000548 WO1993022290A1 (en) | 1992-04-28 | 1993-04-27 | Novel substituted tertiary amino compound or salt thereof |
Country Status (14)
Country | Link |
---|---|
US (1) | US5538976A (ja) |
EP (1) | EP0640595B1 (ja) |
JP (1) | JP2682741B2 (ja) |
KR (1) | KR0163624B1 (ja) |
CN (1) | CN1039228C (ja) |
AT (1) | ATE178056T1 (ja) |
AU (1) | AU4023093A (ja) |
CA (1) | CA2118138A1 (ja) |
DE (1) | DE69324141T2 (ja) |
DK (1) | DK0640595T3 (ja) |
ES (1) | ES2130258T3 (ja) |
GR (1) | GR3030472T3 (ja) |
TW (1) | TW345577B (ja) |
WO (1) | WO1993022290A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014507419A (ja) * | 2011-01-31 | 2014-03-27 | ルコラス−エム.ディー.リミテッド | 医薬的使用 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6756367B2 (en) | 1998-02-03 | 2004-06-29 | Novartis Ag | Benzo-oxadiazoles, -thiadiazoles and -1,4-diazines, pharmaceutical compositions containing them and a process for preparing them |
GB9802251D0 (en) * | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
EP1075486A1 (en) * | 1998-05-06 | 2001-02-14 | Duke University | Method of treating bladder and lower urinary tract syndromes |
AU6589801A (en) * | 2000-04-28 | 2001-11-12 | F. Hoffmann-La Roche Ag | P-(sulfonyl)aryl and heteroaryls |
GB0120147D0 (en) * | 2001-08-17 | 2001-10-10 | Metris Therapeutics Ltd | Treatment method |
GB0127923D0 (en) | 2001-11-21 | 2002-01-16 | Sterix Ltd | Compound |
EP1431292A1 (en) * | 2002-12-16 | 2004-06-23 | Laboratoire Theramex | 1-N-phenylamino-1H-imidazole derivatives as aromatase inhibitors |
AU2007209981B2 (en) * | 2006-02-01 | 2011-11-24 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
DE202009014107U1 (de) | 2009-10-16 | 2010-02-25 | HOKWANG INDUSTRIES CO., LTD., Rueifang | Druckmechanismus eines Seifenspenders mit der Möglichkeit zur Einstellung der Dosiermenge der flüssigen Seife |
CN103183669B (zh) * | 2011-12-27 | 2015-11-18 | 湖南化工研究院 | 噻唑甲胺基吡啶类化合物及其制备方法 |
ES2934684T3 (es) | 2013-03-15 | 2023-02-24 | Abbott Lab | Analizadores de diagnóstico automatizados que tienen carruseles dispuestos verticalmente y métodos relacionados |
CN114137240A (zh) | 2013-03-15 | 2022-03-04 | 雅培制药有限公司 | 具有后面可进入轨道***的自动化诊断分析仪及相关方法 |
WO2014149118A2 (en) | 2013-03-15 | 2014-09-25 | Abbott Laboratories | Diagnostic analyzers with pretreatment carousels and related methods |
CN104387377B (zh) * | 2014-10-14 | 2017-03-29 | 湖南海利常德农药化工有限公司 | 一种噻唑甲胺基吡啶类化合物的制备方法 |
CN105777741B (zh) * | 2014-12-18 | 2019-02-01 | 湖南化工研究院有限公司 | 噻唑烷基吡啶胺类化合物及其制备方法与应用 |
CN104770374B (zh) * | 2015-04-02 | 2017-10-17 | 湖南化工研究院有限公司 | 一种杀菌组合物 |
CN113387894B (zh) * | 2021-06-22 | 2023-02-24 | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 1-n-苯乙腈基氨基-三氮唑和嘧啶衍生物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61122296A (ja) * | 1984-11-13 | 1986-06-10 | チバ‐ガイギー アクチエンゲゼルシヤフト | 新規5‐アミノ‐4‐ヒドロキシバレリル誘導体 |
JPH02275846A (ja) * | 1988-12-29 | 1990-11-09 | Ciba Geigy Ag | カルボン酸誘導体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4762836A (en) * | 1983-02-02 | 1988-08-09 | Eli Lilly And Company | Aromatase inhibitors |
US4774251A (en) * | 1984-06-18 | 1988-09-27 | Eli Lilly And Company | Method of inhibiting aromatase |
US4727060A (en) * | 1984-11-13 | 1988-02-23 | Ciba-Geigy Corporation | Novel 5-amino-4-hydroxyvaleryl derivatives |
DE3905364A1 (de) * | 1989-02-22 | 1990-08-23 | Hoechst Ag | Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool |
-
1993
- 1993-04-27 AU AU40230/93A patent/AU4023093A/en not_active Abandoned
- 1993-04-27 EP EP93909428A patent/EP0640595B1/en not_active Expired - Lifetime
- 1993-04-27 JP JP5519125A patent/JP2682741B2/ja not_active Expired - Fee Related
- 1993-04-27 CA CA002118138A patent/CA2118138A1/en not_active Abandoned
- 1993-04-27 US US08/325,383 patent/US5538976A/en not_active Expired - Fee Related
- 1993-04-27 WO PCT/JP1993/000548 patent/WO1993022290A1/ja active IP Right Grant
- 1993-04-27 KR KR1019940703846A patent/KR0163624B1/ko not_active IP Right Cessation
- 1993-04-27 TW TW082103252A patent/TW345577B/zh active
- 1993-04-27 DK DK93909428T patent/DK0640595T3/da active
- 1993-04-27 AT AT93909428T patent/ATE178056T1/de not_active IP Right Cessation
- 1993-04-27 DE DE69324141T patent/DE69324141T2/de not_active Expired - Fee Related
- 1993-04-27 ES ES93909428T patent/ES2130258T3/es not_active Expired - Lifetime
- 1993-04-28 CN CN93105330A patent/CN1039228C/zh not_active Expired - Fee Related
-
1999
- 1999-06-09 GR GR990401545T patent/GR3030472T3/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61122296A (ja) * | 1984-11-13 | 1986-06-10 | チバ‐ガイギー アクチエンゲゼルシヤフト | 新規5‐アミノ‐4‐ヒドロキシバレリル誘導体 |
JPH02275846A (ja) * | 1988-12-29 | 1990-11-09 | Ciba Geigy Ag | カルボン酸誘導体 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014507419A (ja) * | 2011-01-31 | 2014-03-27 | ルコラス−エム.ディー.リミテッド | 医薬的使用 |
Also Published As
Publication number | Publication date |
---|---|
ES2130258T3 (es) | 1999-07-01 |
EP0640595A4 (en) | 1995-04-12 |
CN1039228C (zh) | 1998-07-22 |
TW345577B (en) | 1998-11-21 |
DE69324141T2 (de) | 1999-08-26 |
EP0640595B1 (en) | 1999-03-24 |
ATE178056T1 (de) | 1999-04-15 |
KR950701321A (ko) | 1995-03-23 |
CN1079962A (zh) | 1993-12-29 |
JP2682741B2 (ja) | 1997-11-26 |
CA2118138A1 (en) | 1993-10-29 |
AU4023093A (en) | 1993-11-29 |
GR3030472T3 (en) | 1999-10-29 |
DK0640595T3 (da) | 1999-10-11 |
US5538976A (en) | 1996-07-23 |
EP0640595A1 (en) | 1995-03-01 |
KR0163624B1 (ko) | 1998-12-01 |
DE69324141D1 (de) | 1999-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993022290A1 (en) | Novel substituted tertiary amino compound or salt thereof | |
KR100926399B1 (ko) | 디아릴아민―함유 화합물 및 조성물, 및 스테로이드 호르몬핵 수용체의 조절제로서의 그들의 용도 | |
FI112867B (fi) | 4-aminopyrrolo[2,3-d]pyrimidiinijohdannaiset ja niiden käyttö | |
KR0174752B1 (ko) | 이환식 헤테로환 함유 술폰아미드 유도체 및 그 제조방법 | |
JP4426660B2 (ja) | ピラゾール誘導体、その製法および医薬としてのその使用 | |
US6133303A (en) | Bicyclic inhibitors of protein farnesyl transferase | |
CZ20011631A3 (cs) | Amidy kyseliny anthranilové, léčiva tyto látky obsahující a jejich pouľití | |
US20100267754A1 (en) | Integrin expression inhibitor | |
JP2002529452A5 (ja) | ||
WO2004052280A2 (en) | Anti-angiogenic compounds and their use in cancer treatment | |
BG107212A (bg) | Заместени амиди на бензоената киселина и използването им за задържане на ангиогенеза | |
EA012206B1 (ru) | Алкильные производные в качестве метаботропных рецепторов глутамата | |
TW200402291A (en) | Antiallergic | |
Shamim et al. | Synthesis and screening of (E)-3-(2-benzylidenehydrazinyl)-5, 6-diphenyl-1, 2, 4-triazine analogs as novel dual inhibitors of α-amylase and α-glucosidase | |
Kumar et al. | Ramachary-Bressy-Wang [3+ 2] cycloaddition reaction: Synthesis of fully decorated 1, 2, 3-triazoles as potent anticancer and EGFR inhibitors | |
JPH06220059A (ja) | 縮合ピリミジン誘導体及びその製法 | |
JP2008266295A (ja) | キナーセ゛阻害活性を有する新規チアシ゛アソ゛ール誘導体 | |
WO2001002349A1 (fr) | Derives phenyl-sulfamates | |
US7459470B2 (en) | N-oxide anthranylamide derivatives and their use as medicaments | |
KR100204697B1 (ko) | 트리아졸릴 치환된 3급 아민 화합물 또는 이의 염 | |
JP4343681B2 (ja) | シアノアントラニルアミド誘導体およびそれらの薬剤としての使用 | |
WO2005113499A1 (ja) | インドール化合物 | |
JP4559849B2 (ja) | 置換2−フェニル−3(2h)−ピリダジノン | |
JP4007743B2 (ja) | 血管新生阻害剤 | |
JPH064623B2 (ja) | イミダゾール誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA CZ FI HU JP KR KZ LK MG MN MW NO NZ PL PT RO RU SD SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2118138 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08325383 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993909428 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1993909428 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993909428 Country of ref document: EP |